In Vitro Model for the Study of the Dissociation of Increasing Antigenemia and Decreasing DNAemia and Viremia during Treatment of Human Cytomegalovirus Infection with Ganciclovir in Transplant Recipients

Journal of Infectious Diseases

Volumn 188, Issue 11, 2003, Pages 1639-1647

  Gerna, Giuseppe ^a   Sarasini, Antonella ^a   Lilleri, Daniele ^a   Percivalle, Elena ^a   Torsellini, Maria ^a   Baldanti, Fausto ^a   Revello, M Grazia ^a  

^a Servizio di Neuroradiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PHOSPHOPROTEIN; PHOSPHOPROTEIN 65; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPRODUCIBILITY; UMBILICAL VEIN; VIREMIA;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENDOTHELIAL CELLS; GANCICLOVIR; HUMANS; NEUTROPHILS; ORGAN TRANSPLANTATION; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

EID: 0346256762     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379376     Document Type: Article

References (34)

1. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61:1659-60.
2. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998; 36:1113-6.
3. Boeckh M, Godey TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88:4063-71.
4. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97:867-74.
5. Gerna G, Percivalle E, Baldanti F, et al. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 2000; 74:5629-38.
6. Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S, Gerna G. In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 1998; 101:2686-92.
7. Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 2003; 75:1012-9.
8. Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101:5053-60.
9. Revello MG, Baldanti F, Percivalle E, et al. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 2001; 82:1429-38.
10. Baldanti F, Simoncini L, Sarasini A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998; 66:324-9.
11. Sarasini A, Baldanti F, Furione M, et al. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J Med Virol 1995; 47:237-44.
12. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet-resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996; 70:1390-5.
13. Underwood MR, Harvey RJ, Stanat SC, et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 1998; 72:717-25.
14. Krosky PM, Underwood MR, Turk SR, et al. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 1998; 72:4721-8.
15. Arevalo JF, Gonzales C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:951-6.
16. Taburet A-M, Katlama C, Blashard C, et al. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother 1992; 36:1821-4.
17. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721-9.
18. Gerna G, Baldanti F, Zavattoni M, Sarasini A, Percivalle E, Revello MG. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res 1992; 19:333-45.
19. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30:1232-7.
20. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36:3585-9.
21. Gerna G, Revello MG, Percivalle E, Zavattoni M, Parea M, Battaglia M. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 1990; 28: 2681-8.
22. Gerna G, Baldanti F, Sarasini A, et al. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. Antimicrob Agents Chemother 1994; 38:38-44.
23. Gerna G, Zavattoni M, Baldanti F, et al. Human cytomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 1998; 65: 1378-85.
24. Muranyi W, Haas J, Wagner M, Krohne G, Koszinowski UH. Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 2002; 297:854-7.
25. Baldick CJ Jr, Shenk T. Proteins associated with purified human cytomegalovirus particles. J Virol 1996; 70:6097-105.
26. Roby C, Gibson W. Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J Virol 1986; 59:714-27.
27. Stinski MF. Human cytomegalovirus: glycoproteins associated with virions and dense bodies. J Virol 1976; 19:594-609.
28. Pepperl S, Münster J, Mach M, Harris JR, Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 2000; 74:6132-46.
29. Fuchs W, Klupp BG, Granzow H, Osterrieder N, Mettenleiter TC. The interacting UL31 and UL34 gene products of pseudorabies virus are involved in egress from the host-cell nucleus and represent components of primary enveloped but not mature virions. J Virol 2002; 76:364-78.
30. L 34 gene product is required for viral envelopment. J Virol 2000; 74:117-29.
31. Sanchez V, Spector DH. CMV makes a timely exit. Science 2002; 297: 778-9.
32. Mocarski ES, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol 2. Philadelphia: Lippincott, Williams, & Wilkins 2001; 2629-73.
33. Schmolke S, Drescher P, Jahn G, Plachter B. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 1995; 69: 1071-8.
34. Gallina A, Percivalle E, Simoncini L, Revello MG, Gerna G, Milanesi G. Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 1996; 77:1151-7.